Author Archives: Diogo Pinto

Bardoxolone Improved Sarcoidosis Patients’ Exercise Ability in Phase 2 Trial

Bardoxolone methyl, an investigational therapy developed by Reata Pharmaceuticals, was shown to significantly improve the exercise capacity of patients with pulmonary hypertension (PH) associated with sarcoidosis in a Phase 2 clinical trial. Bardoxolone is an experimental, oral molecule that promotes the resolution of inflammation by targeting an important mediator…